CAS NO: | 136572-09-3 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
生物活性 |
Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is atopoisomeraseIinhibitor with antitumor activity[1]. |
||||||||||||||||
IC50& Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
Irinotecan hydrochloride trihydrate is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50of 1.3 μM[3].
|
||||||||||||||||
体内研究 (In Vivo) |
Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3].
|
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
677.18 |
||||||||||||||||
性状 |
Solid |
||||||||||||||||
Formula |
C33H45ClN4O9 |
||||||||||||||||
CAS 号 |
136572-09-3 |
||||||||||||||||
中文名称 |
盐酸伊立替康三水合物 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 50 mg/mL(73.84 mM;Need ultrasonic) H2O : 1.52 mg/mL(2.24 mM;Need ultrasonic and warming)
配制储备液
*
请根据半岛bd体育手机客户端 在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的半岛bd体育手机客户端 失效。
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
*
以上所有助溶剂都可在本网站选购。
|